Canada Pension Plan Investment Board
TRDA icon

Canada Pension Plan Investment Board’s Entrada Therapeutics TRDA Stock Holding History

Canada Pension Plan Investment Board’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Sell
17,700
-7,900
-31% -$90.5K ﹤0.01% 1538
2025
Q4 		$263K Buy
+25,600
New +$216K ﹤0.01% 1562

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Canada Pension Plan Investment Board's TRDA Position: Q1 2026 in Review

Canada Pension Plan Investment Board reduced its Entrada Therapeutics (TRDA) stake by 31% in Q1 2026, selling an estimated $90.5K and leaving 17,700 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Canada Pension Plan Investment Board first reported a position in TRDA in Q4 2025 and has held it in 2 quarters since. The position peaked at $263K in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Canada Pension Plan Investment Board held 17,700 shares of Entrada Therapeutics worth $223K as of Q1 2026.
  • Canada Pension Plan Investment Board sold 7,900 Entrada Therapeutics shares in Q1 2026, an estimated $90.5K.
  • Entrada Therapeutics made up ﹤0.01% of Canada Pension Plan Investment Board's portfolio in Q1 2026, its #1538 holding.
  • Canada Pension Plan Investment Board first reported a position in Entrada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Canada Pension Plan Investment Board's Entrada Therapeutics position peaked at $263K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Canada Pension Plan Investment Board's 13F filing for Q1 2026, filed 15 May 2026.